Ficerafusp alfa 2000 mg Q2W plus pembrolizumab as first-line (1L) treatment for HPV-negative recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

ficerafusp alfa (BCA101) - Bicara Therapeutics

Keytruda (pembrolizumab) - Merck (MSD)

https://astro.confex.com/astro/hncs2026/meetingapp.cgi/Paper/72887

Jennifer Choe; Christine Chung; Glenn Hanna; Jonathan Hayman; Ashlee Horgan; John Kaczmar; Brenda O'Connell; Assuntina Sacco; Eric Sherman; Catherine Shu; Tamara Sussman; Deborah Wong; Dan Zandberg

Mar 1, 2026